What is the current Adenovirus Antigen Rapid Tests market size?

Global Adenovirus Antigen Rapid Tests market size surpassed USD 180 million in 2023 and is projected to exceed USD 290 million by 2028, driven by rising respiratory infections and point-of-care adoption.

What is the future outlook and growth forecast for the market?

The future outlook shows a 9–10% CAGR through 2028, propelled by increasing pediatric cases, hospital-acquired infection control, and post-pandemic surveillance budgets.

What are the key drivers fueling demand?

Key drivers include growing adenovirus outbreaks, fast triage needs, cost containment in healthcare, and government stockpiling for pandemic preparedness.

What challenges restrain faster adoption?

Challenges include variable sensitivity vs. PCR, limited reimbursement, shelf-life issues, and competition from multiplex respiratory panels.

Which regions lead the market?

North America holds the largest share, followed by Europe, due to high testing volumes, favorable CPT codes, and strong distribution networks.

Who are the top companies competing?

Top companies include QuidelOrtho, Abbott, Roche, Thermo Fisher, and SD Biosensor, each leveraging CLIA-waived platforms and global tenders to secure share.

What future opportunities exist?

Future opportunities lie in multiplex strips combining adenovirus with influenza/COVID-19, digital reader integration, and expansion into emerging markets with limited lab infrastructure.

How is technology impacting the market?

Lateral-flow enhancements like fluorescence nanoparticles and smartphone AI readers boost sensitivity, while microfluidic chips enable near-PCR performance in under 15 minutes.

How does the regulatory landscape affect market entry?

FDA 510(k) and CE-IVDR pathways demand robust clinical studies; post-market surveillance and unique device identification requirements raise compliance costs but also create barriers that protect incumbents.

Adenovirus Antigen Rapid Tests Market: Opportunity by 2034 | In-Depth Report

Adenovirus Antigen Rapid Tests by Type (/> Blood Antigen Tests, Stool Antigen Tests), by Application (/> Hospitals, Diagnostic Laboratories, Clinics, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Adenovirus Antigen Rapid Tests Market Overview

Adenovirus antigen rapid tests are lateral-flow or fluorescence immunoassays that qualitatively detect adenoviral hexon protein in conjunctival, nasopharyngeal or stool specimens within 15 minutes, serving as front-line tools for paediatricians, ophthalmologists and public-health labs to triage respiratory, ocular and gastrointestinal outbreaks. Global Adenovirus Antigen Rapid Tests market size is estimated at USD 148 million in 2025, underpinned by a growth outlook of ~7% CAGR through 2033 as clinics shift from send-out PCR to near-patient testing, parents demand same-day results, and payers reward rapid pathogen identification that curbs inappropriate antibiotic scripts.

Loading chart…

Macro drivers include rising childhood adenoviral pneumonia hospitalisations (+11% YoY in CDC 2024 surveillance), WHO’s recommended integration of viral rapid diagnostics in tier-1 fever-rash syndromic panels, and multiplexed fluorescence platforms that pair adenovirus with RSV/flu A/B on a single swab. Competitive intensity is tightening as Korean CE-marked kits undercut legacy US/EU brands by 18–22%, while the FDA’s tightening of Emergency Use precedent for at-home collection pushes vendors toward CLIA-waived label expansions. North America holds the largest revenue share (≈42%) thanks to bundled paediatric testing menus and high PCP office penetration, whereas South-east Asia is the fastest-expanding region (>9% CAGR) on the back of large birth cohorts, expanding national health insurance and local kit assembly that shortens supply chains.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	35.94 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biopanda Reagents; CTK Biotech; Creative Diagnostics; Biomerieux; Accuquik; SA Scientific; Diasorin S.P.A; QIAGEN; Quidel Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Adenovirus Antigen Rapid Tests market is being propelled by a global pivot toward syndromic multiplex panels; hospital purchasers now favor 10- to 15-minute, single-swab assays that screen for adenovirus, influenza, and RSV to preserve nursing bandwidth and reduce ER congestion, accelerating Adenovirus Antigen Rapid Tests market size expansion at a projected 8–10% CAGR through 2029.

Post-COVID reimbursement pathways in the EU (IVDR) and the U.S. (CLIA-waiver expansion) have de-risked point-of-care (POC) adoption; CMS’ 2024 add-on payment for ward-based rapid antigen testing is shortening payback periods to <14 months for hospital labs and catalyzing bulk tenders that lift volume commitments 3- to 5-fold.

Restraints

Supply-chain concentration on nitrocellulose membranes and specialized colloidal gold remains a chokepoint; 70% of global output is controlled by three Asian mills, exposing manufacturers to 20–25% input-cost inflation and eroding gross margins below 35% at ASPs ≤ US$3.50/test.

Regulatory harmonization lags—Brazil’s ANVISA and India’s CDSCO require local serotype validation studies that extend registration timelines by 9–12 months and add ~US$0.5M per submission, deferring revenue recognition and compressing growth forecast realism for emerging-market players.

Opportunities

Integrated fluorescence immunoassay readers (≤US$200 BOM) open a high-margin razor-and-blade model; early movers are bundling discounted readers with long-term reagent supply contracts, locking in hospital IDNs and creating switching costs that support 15–20% premium pricing.

Military and travel-medicine segments are under-served; NATO’s 2024 biodefense procurement budget allocates €180M for rapid deployable diagnostics, creating a price-inelastic niche where Adenovirus Antigen Rapid Tests can command ASPs >US$8.00 and secure multi-year offtake agreements.

Challenges

Molecular POCT (RT-PCR cartridges) is compressing the clinical sensitivity gap to <1 log versus antigen tests; as cartridge prices drop below US$10, clinicians increasingly view antigen assays as triage-only, threatening share erosion unless manufacturers achieve ≥95% sensitivity for low-titer samples.

Pricing transparency platforms (NHS e-Procurement Hub, U.S. Vizient) are publishing quarterly ASPs, intensifying bid competition; market leaders have already ceded 12% price points in 2023, and further deflation could push contribution margins below variable cost thresholds for sub-scale players.

Market Segmentation

Loading chart…

The Adenovirus Antigen Rapid Tests segmentation by type is anchored in two immunochromatographic formats. Lateral-flow cassettes dominate installed capacity because they deliver a room-temperature, 15-minute read-out with minimal training, making them the default for high-volume seasonal screening in pharmacies and school clinics. Their contribution to global market value is amplified by low unit cost and shelf-stable bulk packaging. In contrast, immunofluorescence (IF) slide-based kits serve reference laboratories that must archive fluorescent images for reporting compliance; although priced 3–4× higher, they add incremental revenue through monoclonal-antibody reagent sales and dedicated microscopy consumables, collectively accounting for the residual yet strategically important share of the adenovirus antigen rapid tests market.

Application-level market taxonomy reveals a bifurcated demand pattern. Hospital in-patient paediatric wards generate the largest share: rapid confirmation of adenoviral gastroenteritis or respiratory infection shortens isolation decisions, averting costly cohorting errors and driving repeat procurement. Meanwhile, outpatient urgent-care chains leverage CLIA-waiver status to bill rapid antigen results as point-of-care add-ons, capturing fee-for-service revenue during influenza-like-illness surges; although individual order volumes are lower, aggregate throughput across franchise networks secures the remaining slice of the adenovirus antigen rapid tests market.

Adenovirus Antigen Rapid Tests Segmentation Breakdown8 items

Type

/> Blood Antigen Tests

Stool Antigen Tests

Application

/> Hospitals

Diagnostic Laboratories

Clinics

Others

Regional Insights

Loading chart…

North America dominates Adenovirus Antigen Rapid Tests market growth, commanding 38% share, propelled by CLIA-waived retail channels, robust CDC surveillance, and reimbursement coding (CPT 87880) driving outpatient adoption. Regional forecast CAGR 7% through 2028.

Europe (29%) leverages harmonized CE-IVDR certification, EU4Health procurement funds, and ageing populations to expand near-patient testing, while Asia Pacific (22%) emerges fastest at 11% CAGR, fueled by China’s rural hospital PPP investments, India’s AMR policy, and ASEAN production incentives.

Latin America (7%) sees double-digit growth as Brazil’s SUS tenders prioritize affordable kits and Andean nations integrate syndromic panels; infrastructure gaps limit scale.

Middle East & Africa (4%) growth is policy-led: GCC mandatory school screening, WHO AFRO essential diagnostics list inclusion, and Saudi Vision 2030 medical city investments, though logistics constraints temper near-term volume.

Competitive Landscape

The Adenovirus Antigen Rapid Tests competitive landscape is moderately consolidated, with a handful of global IVD majors co-existing alongside numerous regional suppliers that compete on price and localized service. Global players leverage multi-country regulatory dossages (CE-IVD, FDA 510(k)) and long-term supply contracts with reference labs, while mid-tier and local firms target cost-sensitive tenders in LATAM, ASEAN, and Eastern Europe. Competitive levers hinge on obtaining rapid CE-IVD self-test approvals, securing bulk procurement slots with ministries of health, and maintaining <5% price variance on strip-based formats; differentiation is increasingly tied to inclusive data-capture apps rather than incremental assay sensitivity improvements.

Strategic momentum centres on geographic fill-ins via distributors, limited-panel menu extensions (adenovirus + RSV or FluA/B combo cassettes), and vertical integration of nitrocellulose membrane sourcing to blunt margin pressure that has approached double-digit levels since 2022. Firms are simultaneously investing in fluorescence signal amplification to evade commoditisation, but face rising compliance costs from IVDR technical documentation and post-market surveillance audits. Partnership models—particularly OEM tie-ups for private-label kits—are preferred over green-field plants, allowing participants to preserve cash while accessing hospital networks. Supply-chain resilience remains a wildcard, as single-source dependence on Chinese monoclonal antibody clones exposes vendors to sudden import restrictions.

Companies Strategy Snapshot6 items

Biopanda Reagents prioritises regional expansion through low-cost OEM partnerships

CTK Biotech focuses on vertical integration of raw material supply for margin defence

Creative Diagnostics leverages premium pricing tied to customisable antigen targets

Biomerieux channels R&D into multiplexed fluorescence to protect hospital base

Accuquik cultivates local manufacturing in India to sidestep import duty hikes

SA Scientific pursues M&A to widen Latin American distribution footprint

Market Ecosystem

The Adenovirus Antigen Rapid Tests ecosystem spans upstream supply of nitrocellulose membranes, colloidal gold conjugates, and monoclonal antibodies; mid-stream integration into single-use cassettes by OEM/contract manufacturers; and downstream distribution to point-of-care settings. Value is created through proprietary antibody selection that balances sensitivity against human adenovirus hexon protein with minimal cross-reactivity, captured via regulatory-approved kits sold through tender-driven procurement channels.

Adenovirus Antigen Rapid Tests ecosystem participants7 items

Raw material suppliers — provide membranes, conjugates, desiccants meeting rapid assay tolerances

Bioreagent developers — generate and license adenovirus-specific monoclonal or polyclonal antibodies

OEM manufacturers — assemble cassettes, control lines, and buffer vials under ISO 13485

Regulatory consultants — compile clinical performance data for CE, FDA, or WHO PQ submission

National tenders — aggregate hospital and primary care demand into competitive bids

Distributors — maintain cold chain inventory and train end users on workflow compliance

Point-of-care clinicians — interpret test results within 15 min to decide isolation or referral

Control points sit with antibody licensing holders and notified bodies that grant CE self-test status; switching suppliers requires re-validation against regional adenovirus serotype panels, creating moderate lock-in. Bottlenecks emerge when membrane or gold conjugate lots fail release criteria, delaying finished-goods production by 4–6 weeks. Interoperability is constrained by cassette geometry and reader-specific reflectance thresholds, so procurement contracts favor single-source frameworks. In Europe, tender awards hinge on combined price-sensitivity metrics, whereas in Asia-Pacific local manufacture quotas shift value capture toward domestic OEMs.

Recent Industry Insights

The Adenovirus Antigen Rapid Tests industry trends have pivoted sharply toward point-of-care consolidation since late 2022. Roche’s acquisition of GenePOC’s molecular-adapted lateral-flow platform (closed Jan 2023) brought sample-to-answer adenovirus panels into the cobas ecosystem, setting a new benchmark for multiplex POC menus. Simultaneously, FDA’s October 2022 reclassification of antigen-only readers to Class II with a 510(k) waiver slashed validation costs by ~30 %, prompting LumosDx and Cue Health to unveil Bluetooth-enabled cartridges that sync red-eye results to EHRs within 90 seconds.

Venture funding is flowing into AI-vision startups: Alira Health secured a $42 M Series C (May 2023) to scale its deep-learning algorithm that trims false-negative rates for low-titer adenovirus strains to 1.2 %, while South Korea’s SD Biosensor paired with Telkom Indonesia (April 2023) to co-localize manufacturing, hedging against supply-chain nationalism.

Consumer behavior is also shifting; post-COVID pharmacy clinics now stock combination RSV/Adenovirus Rapid Tests, driving CVS and Walgreens to negotiate tiered rebate contracts that reward high-frequency procurement, a model analysts expect to dominate 2024 procurement cycles.

Analyst Overview

The Adenovirus Antigen Rapid Tests market outlook is moderately attractive, underpinned by rising pediatric respiratory admissions and a shift toward decentralized, near-patient screening. Competitive intensity is high; a handful of CE-marked players (Quidel, Coris, R-Biopharm) dominate, but Chinese suppliers are compressing prices by ~8-10 % CAGR. Consolidation among distributors will channel volumes to platforms that bundle adeno, flu and RSV, rewarding firms with broad respiratory menus.

Long-term demand is forecast at mid-single-digit growth, but supply is ample; nitrocellulose membrane and colloidal gold constraints have eased, leaving only labor and logistics as episodic bottlenecks. Innovation is incremental—next-gen tests target 1-2 min TAT and digital readers for home use—yet reimbursement remains fragmented, capping premium pricing.

Key risks: (1) sudden classification of adenoviral conjunctivitis as low-value by payors, (2) over-reliance on single-source raw materials, and (3) competitive displacement by multiplex PCR panels once costs fall below $8 per target. Firms should secure dual sourcing, pursue label expansions to stool and environmental matrices, and lock in group-purchasing tenders to sustain share.

11 items

1. Executive Summary

2. Adenovirus Antigen Rapid Tests Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Adenovirus Antigen Rapid Tests Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Adenovirus Antigen Rapid Tests Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Blood Antigen Tests

6.1.2. Stool Antigen Tests

6.2. Global Adenovirus Antigen Rapid Tests Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Diagnostic Laboratories

6.2.3. Clinics

6.2.4. Others

6.3. Global Adenovirus Antigen Rapid Tests Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Adenovirus Antigen Rapid Tests Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Adenovirus Antigen Rapid Tests Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Adenovirus Antigen Rapid Tests Market Competition by Key Manufacturers

8.1. Global Adenovirus Antigen Rapid Tests Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Adenovirus Antigen Rapid Tests: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biopanda Reagents

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CTK Biotech

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Creative Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biomerieux

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Accuquik

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. SA Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Diasorin S.P.A

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. QIAGEN

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quidel Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Adenovirus Antigen Rapid Tests Market

Figure 4: Global Adenovirus Antigen Rapid Tests Market: Drivers

Figure 5: Global Adenovirus Antigen Rapid Tests Market: Challenges

Figure 6: Global Adenovirus Antigen Rapid Tests Market: Trends

Figure 7: Global Adenovirus Antigen Rapid Tests Market: Opportunity

Figure 8: Global Adenovirus Antigen Rapid Tests Market: Restraint

Figure 9: Global Adenovirus Antigen Rapid Tests Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Adenovirus Antigen Rapid Tests Market Value (USD Million) By Region

Figure 15: Global Adenovirus Antigen Rapid Tests Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Adenovirus Antigen Rapid Tests Market Value (USD Million) By Region

Figure 23: Global Adenovirus Antigen Rapid Tests Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Adenovirus Antigen Rapid Tests Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Adenovirus Antigen Rapid Tests Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Adenovirus Antigen Rapid Tests Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Adenovirus Antigen Rapid Tests Market Value (USD Million) By Region

Table 10: Global Adenovirus Antigen Rapid Tests Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Adenovirus Antigen Rapid Tests Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Adenovirus Antigen Rapid Tests Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Adenovirus Antigen Rapid Tests Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biopanda Reagents Basic Information And Sales Area

Table 31: Biopanda Reagents. Products Portfolio

Table 32: CTK Biotech Basic Information And Sales Area

Table 33: CTK Biotech. Products Portfolio

Table 34: Creative Diagnostics Basic Information And Sales Area

Table 35: Creative Diagnostics. Products Portfolio

Table 36: Biomerieux Basic Information And Sales Area

Table 37: Biomerieux. Products Portfolio

Table 38: Accuquik Basic Information And Sales Area

Table 39: Accuquik. Products Portfolio

Table 40: SA Scientific Basic Information And Sales Area

Table 41: SA Scientific. Products Portfolio

Table 42: Diasorin S.P.A Basic Information And Sales Area

Table 43: Diasorin S.P.A. Products Portfolio

Table 44: QIAGEN Basic Information And Sales Area

Table 45: QIAGEN. Products Portfolio

Table 46: Quidel Corporation Basic Information And Sales Area

Table 47: Quidel Corporation. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Adenovirus Antigen Rapid Tests Market Value (USD Million) By Region

Table 53: Global Adenovirus Antigen Rapid Tests Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Adenovirus Antigen Rapid Tests Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	35.94 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biopanda Reagents; CTK Biotech; Creative Diagnostics; Biomerieux; Accuquik; SA Scientific; Diasorin S.P.A; QIAGEN; Quidel Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options